Skip to main content

UBS Group AG

Position in VKTX — Viking Therapeutics, Inc.

CIK 1610520 ZURICH, V8

Position in VKTX

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$43,846,738
+$10,956,079 QoQ
Shares Held
1,347,472
+44.1% QoQ
Ownership
1.16%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 91.39173207309688.ToString("F0")% Shared 0.ToString("F0")% None 8.60826792690312.ToString("F0")%

Common Shares in VKTX Over Time

Shares Held

Position Value (USD)

Derivatives in VKTX

reported options exposure · as of Dec 31, 2025
CallValue
$1,400,164
CallShares
39,800
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. VKTX ranks #45 (0.5% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in VKTX

Export CSV
29 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $43,846,738 1,347,472
2025-12-31 $1,400,164 39,800
2025-12-31 $32,890,659 934,925
2025-09-30 $1,839,600 70,000
2025-09-30 $35,275,852 1,342,308
2025-06-30 $25,215,464 951,527
2025-03-31 $14,409,337 596,660
2024-12-31 $24,874,272 618,148
2024-09-30 $20,826,393 328,959
2024-06-30 $19,050,837 359,382
2024-06-30 $1,404,765 26,500
2024-03-31 $22,472,592 274,056
2023-12-31 $6,322,299 339,726
2023-09-30 $1,590,880 143,711
2023-06-30 $2,545,909 157,058
2023-03-31 $3,117,078 187,212
2022-12-31 $432,850 46,048
2022-09-30 $111,702 41,067
2022-06-30 $122,260 42,305
2022-03-31 $229,086 76,362
2021-12-31 $1,527,939 332,161
2021-09-30 $1,700,711 270,814
2021-06-30 $1,006,493 168,029
2021-03-31 $1,932,881 305,594
2020-12-31 $477,980 84,899
2020-09-30 $1,958,237 336,467
2020-06-30 $2,384,209 330,681
2020-03-31 $1,828,040 390,607
2020-03-31 $468 100